Pipeline

Chrysalis is pioneering the use of natural peptide regenerative drugs to restore vascular function and activate normal stem cell populations where they exist in the body. Our lead product TP508 has demonstrated potential for clinical benefit in human clinical trials and in preclinical studies for multiple clinical indications. Chrysalis has utilized non-dilutive funding to build a diverse pipeline with partnering opportunities, but is focused on mitigating effects of radiation and preventing cognitive dysfunction caused by neurotrauma and brain cancer radiation therapy. The TP508 Nuclear Countermeasure Program funded by NIH and BARDA is being developed under the FDA Animal Rule program with potential approval by 2024.
DERMAL/SOFT TISSUE Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA
Diabetic Foot Ulcers
Burns
RADIATION THERAPY Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA
Brain Cancer
Radiation Dermatitis/Delayed Healing
NEURAL REGENERATION Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA
Traumatic Brain Injury
Degenerative Disease
NUCLEAR COUNTERMEASURE Animal Rule PRE-IND IND Pivotal Trial Approval
Acute & Delayed Radiation Syndromes
Topical/Oral
Injectable
Middle of Non Clinical_Oral
Middle of Non Clinical_Injectable
End of Non Clinical_Oral
End of Non Clinical_Injectable
IND_Injectable
Middle of Phase 1_Oral
Middle of Phase 1_Injectable
Middle of Phase 2